


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-10.54%
+6.99%
+9.81%
-25.94%
+0.58%
DOCS
Doximity
$43.65
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Investors confidence is positive
Risk Analysis

Trading above its fair value
DOCS Price Performance
$49.95 (-12.61%)
$74.4 (-41.33%)
$58.3 (-25.13%)
$55.57 (-21.45%)
DOCS has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

DOCS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading above its fair value

Outperform the market
![]()
DOCS Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
DOCS Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
What is DOCS current stock price?
What are DOCS stock strengths?
What is DOCS Risk Level?
What is DOCS market cap and volume?
What is DOCS current Stock IQ?
Should I buy DOCS stock right now?
Is DOCS a Strong Buy right now?
What does a 'Strong Buy' rating mean for DOCS?
What does a 'Strong Sell' rating mean for DOCS?
What factors influence DOCS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-10.54%
+6.99%
+9.81%
-25.94%
+0.58%
DOCS
Doximity
Current Price
$43.65
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Investors confidence is positive
Risk Analysis

Trading above its fair value

DOCS Price Performance
$49.95 (-12.61%)
$74.4 (-41.33%)
$58.3 (-25.13%)
$55.57 (-21.45%)
DOCS Analysts Opinion
DOCS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading above its fair value

Outperform the market
![]()
DOCS Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
DOCS Street Sentiment is extremely bullish and have positive views on the near-term outlook
DOCS has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
DOCS Stock IQ
DOCS Latest Analysis
Morgan Stanley Upgrades Doximity (DOCS). Fintel reports that on December 15 2025 Morgan Stanley upgraded their outlook for Doximity (NYSE:DOCS) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 59.15% Upside
Mon Dec 15, 2025
Doximity upgraded at Morgan Stanley on expanding market for HCP platforms.
Mon Dec 15, 2025
Morgan Stanley says buy this health tech platform after 30% correction in the past month. Morgan Stanley sees shares of Doximity rising 48% from here.
Mon Dec 15, 2025
Barclays Initiates Coverage of Doximity (DOCS) with Overweight Recommendation. Fintel reports that on December 9 2025 Barclays initiated coverage of Doximity (NYSE:DOCS) with a Overweight recommendation. Analyst Price Forecast Suggests 52.78% Upside
Wed Dec 10, 2025
Illinois Rep. Jonathan Jackson Sold Up to $80K Worth of Doximity Stock. Records from December 5 2025 indicate that Representative Jonathan Jackson of Illinois made a sale of Doximity (NYSE:DOCS) valued between $17003 and $80000 with the transaction dated November 6 2025 and filed in December.As of now Doximity shares are trading up 0.48% at $46.15.Over the past three years Jonathan Jackson executed 144 trades totaling over $1.78 million. The largest of these trades were in Honeywell Intl and App
Mon Dec 8, 2025
Oversold Conditions For Doximity (DOCS). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me
Fri Dec 5, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
DOCS Stock trends
DOCS Stock performance
DOCS Stock analysis
DOCS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.